Ignite Creation Date:
2024-05-06 @ 8:06 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06256224
Status:
RECRUITING
Last Update Posted:
2024-04-24
First Post:
2024-02-05
Brief Title:
Toripalimab Combined With Definitive CCRT for LACC Patients
Sponsor:
Ruijin Hospital
Organization:
Ruijin Hospital
Study Overview
Official Title:
Toripalimab Combined With Definitive Chemoradiotherapy for Locally Advanced Cervical Squamous Cell Carcinoma Patients
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cervical cancer constitutes a significant health burden for women globally While most patients with early-stage disease can be cured with radical surgery or chemoradiotherapy patients with high-risk locally advanced disease or with recurrentmetastatic disease have a poor prognosis with standard treatments Immunotherapies are a rational treatment for this HPV-driven cancer that commonly expresses programmed cell death ligand-1 Toripalimab a humanized immunoglobulin G4 monoclonal antibody against PD-1 showed promising anti-tumor efficacy in multiple solid tumors This randomised study is evaluating toripalimab combined with CCRT versus CCRT alone for treatment-naïve LACC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None